



Press release from Emotra AB (publ)

Göteborg, February 26, 2020

## **Correction regarding the publication date for our Q1-2020 report**

**Correction: Emotra's Year-end report for 2019 stated the wrong publication date for our interim report for the first quarter 2020. The correct date is May 29, 2020.**

### **Future Reports**

Interim report for January – March, 2020

May 29, 2020

Interim report for January – June, 2020

August 25, 2020

Interim report for January – September, 2020

November 4, 2020

Year-end report for 2020

February 24, 2021

The Annual General Meeting will be held in Göteborg at 11 am on June 3, 2020. The Annual Report will be available at the Company's web site [www.emotra.se](http://www.emotra.se) at least three weeks before the meeting and can also be ordered from the Company by e-mail addressed to [daniel@emotra.se](mailto:daniel@emotra.se).

### **For further information about Emotra, please contact:**

Daniel Poté, CEO, telephone: +46 73 234 41 93, E-mail: [daniel@emotra.se](mailto:daniel@emotra.se)

---

*Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR<sup>®</sup>, is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.*

Emotra AB (publ), AstraZeneca BioVentureHub, Pepparedsleden 1  
SE-431 83 Mölndal, Sweden. Tel: +46 73 234 41 93, [www.emotra.se](http://www.emotra.se)